New antimalarial drugs.

A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A (2008) 3.56

Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci (2006) 2.09

Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43

Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg Med Chem Lett (2008) 1.17

The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep (2013) 1.14

Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem (2006) 0.95

Deciphering the late biosynthetic steps of antimalarial compound FR-900098. Chem Biol (2010) 0.93

Differential effect of artemisinin against cancer cell lines. Nat Prod Bioprospect (2014) 0.91

The mechanism of antimalarial action of the ruthenium(II)-chloroquine complex [RuCl(2)(CQ)] (2). J Biol Inorg Chem (2008) 0.90

Validation of ELISA for quantitation of artemisinin-based antimalarial drugs. Am J Trop Med Hyg (2013) 0.88

Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones. Bioorg Med Chem (2010) 0.87

EGCG induces human mesothelioma cell death by inducing reactive oxygen species and autophagy. Cancer Cell Int (2013) 0.86

Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stages. Malar J (2011) 0.84

Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics (2009) 0.83

A plausible mechanism for the antimalarial activity of artemisinin: A computational approach. Sci Rep (2013) 0.83

Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. J Med Chem (2008) 0.82

Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg Med Chem Lett (2009) 0.81

Concise stereocontrolled formal synthesis of (+/-)-quinine and total synthesis of (+/-)-7- hydroxyquinine via merged Morita-Baylis-Hillman-Tsuji-Trost cyclization. J Org Chem (2008) 0.81

Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem (2011) 0.81

Synthesis and evaluation of chirally defined side chain variants of 7-chloro-4-aminoquinoline to overcome drug resistance in malaria chemotherapy. Antimicrob Agents Chemother (2016) 0.80

Reversal of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR by LY980503. World J Gastroenterol (2007) 0.78

Evaluation of the In Vitro Efficacy of Artemisia annua, Rumex abyssinicus, and Catha edulis Forsk Extracts in Cancer and Trypanosoma brucei Cells. ISRN Biochem (2013) 0.78

4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity. J Med Chem (2013) 0.78

Huprines as a new family of dual acting trypanocidal-antiplasmodial agents. Bioorg Med Chem (2011) 0.76

Molecular docking and 3D-quantitative structure activity relationship analyses of peptidyl vinyl sulfones: Plasmodium Falciparum cysteine proteases inhibitors. J Comput Aided Mol Des (2011) 0.76

Structure-guided design and biosynthesis of a novel FR-900098 analogue as a potent Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr) inhibitor. Chem Commun (Camb) (2015) 0.76

RECENT SYNTHETIC DEVELOPMENTS AND APPLICATIONS OF THE ULLMANN REACTION. A REVIEW. Org Prep Proced Int (2013) 0.76

Studies of one-pot double couplings on dibromoquinolines. Tetrahedron (2011) 0.75

Anti-Oncogenic gem-Dihydroperoxides Induce Apoptosis in Cancer Cells by Trapping Reactive Oxygen Species. Int J Mol Sci (2016) 0.75

Localization and in-Vivo Characterization of Thapsia garganica CYP76AE2 Indicates a Role in Thapsigargin Biosynthesis. Plant Physiol (2017) 0.75

The Eighth Central European Conference "Chemistry towards Biology": Snapshot. Molecules (2016) 0.75

Preparation and characterization of micronized artemisinin via a Rapid Expansion of Supercritical Solutions (RESS) Method. Int J Mol Sci (2012) 0.75

Microbial isoprenoid biosynthesis and human gammadelta T cell activation. FEBS Lett (2003) 2.30

Fosmidomycin for malaria. Lancet (2002) 2.03

The interplay between classical and alternative isoprenoid biosynthesis controls gammadelta T cell bioactivity of Listeria monocytogenes. FEBS Lett (2004) 1.93

In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob Agents Chemother (2002) 1.65

RlmN and Cfr are radical SAM enzymes involved in methylation of ribosomal RNA. J Am Chem Soc (2010) 1.60

Structure of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway. J Am Chem Soc (2008) 1.57

LytB protein catalyzes the terminal step of the 2-C-methyl-D-erythritol-4-phosphate pathway of isoprenoid biosynthesis. FEBS Lett (2002) 1.55

Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother (2003) 1.46

Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy. J Immunol (2007) 1.42

Fosmidomycin for the treatment of malaria. Parasitol Res (2002) 1.40

Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother (2006) 1.35

Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis (2004) 1.35

Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis (2004) 1.34

Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques. J Immunol (2007) 1.32

The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum. J Biol Chem (2004) 1.31

Functional characterization of GcpE, an essential enzyme of the non-mevalonate pathway of isoprenoid biosynthesis. FEBS Lett (2002) 1.17

Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. J Leukoc Biol (2006) 1.08

Differentiation of human gamma-delta T cells towards distinct memory phenotypes. Cell Immunol (2002) 1.07

Antigen-specific Vgamma2Vdelta2 T effector cells confer homeostatic protection against pneumonic plaque lesions. Proc Natl Acad Sci U S A (2009) 1.05

Crystal structure of 1-deoxy-D-xylulose-5-phosphate reductoisomerase, a crucial enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. J Biol Chem (2001) 1.05

Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways. PLoS One (2011) 1.04

Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors. Bioorg Med Chem Lett (2006) 1.03

Double ester prodrugs of FR900098 display enhanced in-vitro antimalarial activity. Arch Pharm (Weinheim) (2007) 1.03

Isoprenoid biosynthesis of the apicoplast as drug target. Curr Drug Targets (2007) 1.03

Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog (2013) 1.02

The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally regulated by Dxs. J Bacteriol (2010) 1.02

Human Vgamma9/Vdelta2 effector memory T cells express the killer cell lectin-like receptor G1 (KLRG1). J Leukoc Biol (2004) 1.02

Reconstitution of an apicoplast-localised electron transfer pathway involved in the isoprenoid biosynthesis of Plasmodium falciparum. FEBS Lett (2005) 1.00

Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates. Bioorg Med Chem (2007) 1.00

Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits. J Immunol (2009) 0.99

Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother (2005) 0.99

Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew Chem Int Ed Engl (2004) 0.98

Accumulation of a potent gammadelta T-cell stimulator after deletion of the lytB gene in Escherichia coli. Immunology (2002) 0.98

Possible direct involvement of the active-site [4Fe-4S] cluster of the GcpE enzyme from Thermus thermophilus in the conversion of MEcPP. FEBS Lett (2006) 0.97

Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase complexes. J Am Chem Soc (2004) 0.97

Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues. Arch Pharm (Weinheim) (2007) 0.96

Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides. Bioorg Med Chem Lett (2002) 0.95

Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity. Bioorg Med Chem Lett (2003) 0.94

Paramagnetic intermediates of (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase (GcpE/IspG) under steady-state and pre-steady-state conditions. J Am Chem Soc (2010) 0.94

Structure of the E-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate synthase (GcpE) from Thermus thermophilus. FEBS Lett (2010) 0.94

Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. Int J Parasitol (2006) 0.93

Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism. Bioorg Med Chem Lett (2003) 0.93

Towards new antimalarial drugs: synthesis of non-hydrolyzable phosphate mimics as feed for a predictive QSAR study on 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors. Chem Biodivers (2008) 0.91

Synthesis of analogues of (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate, an isoprenoid precursor and human gamma delta T cell activator. J Org Chem (2008) 0.90

Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. Antimicrob Agents Chemother (2007) 0.89

Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives. Int J Antimicrob Agents (2011) 0.88

Mycoplasma penetrans is capable of activating V gamma 9/V delta 2 T cells while other human pathogenic mycoplasmas fail to do so. Infect Immun (2004) 0.87

Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents. ChemMedChem (2013) 0.87

Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Arch Pharm (Weinheim) (2005) 0.86

Divergent strategy for the synthesis of alpha-aryl-substituted fosmidomycin analogues. J Org Chem (2007) 0.86

Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors. Bioorg Med Chem Lett (2007) 0.86

Analysis of the isoprenoid biosynthesis pathways in Listeria monocytogenes reveals a role for the alternative 2-C-methyl-D-erythritol 4-phosphate pathway in murine infection. Infect Immun (2008) 0.85

Antimalarial activity of n(6)-substituted adenosine derivatives (part 2). J Comb Chem (2002) 0.85

Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors. J Med Chem (2006) 0.82

Studies addressing the importance of charge in the binding of fosmidomycin-like molecules to deoxyxylulosephosphate reductoisomerase. ChemMedChem (2008) 0.82

Structure of the (E)-4-hydroxy-3-methyl-but-2-enyl-diphosphate reductase from Plasmodium falciparum. FEBS Lett (2013) 0.81

Anti-malarial activity of N(6)-substituted adenosine derivatives. Part I. Bioorg Med Chem (2002) 0.81

Structure of the GcpE (IspG)-MEcPP complex from Thermus thermophilus. FEBS Lett (2012) 0.81

Synthesis of the antimalarial drug FR900098 utilizing the nitroso-ene reaction. Org Lett (2007) 0.81

Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity. Eur J Med Chem (2005) 0.79

Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. Bioorg Med Chem Lett (2003) 0.79

Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells. Immunology (2004) 0.79

Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. J Med Chem (2005) 0.79

Primary MHC-class II(+) cells are necessary to promote resting Vδ2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and isopentenyl pyrophosphate. J Immunol (2012) 0.79

Determination of fosmidomycin in human serum and urine by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.78

Antimalarial and antitrypanosomal activity of a series of amide and sulfonamide derivatives of a 2,5-diaminobenzophenone. Bioorg Med Chem (2009) 0.78

Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology (2006) 0.78

Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials. ChemMedChem (2008) 0.77

Antimalarial activity of N(6)-substituted adenosine derivatives. Part 3. Bioorg Med Chem (2004) 0.77

Structure-based optimization of aldose reductase inhibitors originating from virtual screening. ChemMedChem (2009) 0.76

Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides. Bioorg Med Chem (2004) 0.76

Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors. Arch Pharm (Weinheim) (2003) 0.76

A genetic basis for human gammadelta T-cell reactivity towards microbial pathogens. Trends Immunol (2003) 0.76

[M2 inhibitors and neuraminidase inhibitors]. Pharm Unserer Zeit (2011) 0.76

Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones. Bioorg Med Chem (2002) 0.75

Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides. Bioorg Med Chem Lett (2002) 0.75

The antimalarial pipeline--an update. Int J Med Microbiol (2012) 0.75

Non-thiol farnesyltransferase inhibitors: evaluation of different AA(X)-peptidomimetic substructures in combination with arylic cysteine replacements. Arch Pharm (Weinheim) (2002) 0.75